BAP1tism of a tumor suppressor

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 323-325

  Woodman, Scott E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; TUMOR MARKER; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAP1 GENE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RESEARCH; CANCER SURVIVAL; CELL DIFFERENTIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MALIGNANT MESOTHELIOMA; MELANOMA CELL; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RISK FACTOR; TUMOR SUPPRESSOR GENE; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MELANOMA; UVEAL NEOPLASMS;

EID: 84856011732     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2870     Document Type: Article

References (13)

1. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012;18:408-16.
2. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
3. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006;46:151-66. (Pubitemid 44124237)
4. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
5. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996;93:5705-8. (Pubitemid 26191313)
6. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-7.
7. Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010;9:2663-73.
8. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T,Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
9. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
10. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
11. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48:856-9.
12. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-61. (Pubitemid 43280028)
13. ClinicalTrials.gov. Bethesda (MD): NIH. NCT00128102. A phase III, randomized, double-blind, placebo-controlled trial of oral suberoylanilide hydroxamic acid (vorinostat, MK-0683) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy. Available from: http://clinicaltrials.gov/ct2/show/NCT00128102?term=NCT00128102&rank= 1.